Profile: Oragenics Inc (OGEN.A)
14 Mar 2014
Oragenics, Inc., incorporated on November 6, 1996, is focused on the discovery, development and commercialization of a range of technologies associated with oral health, antibiotics and other general health benefits. The Company is developing and seeking partners or commercializing four products, including ProBiora3, LPT3-04, SMaRT Replacement Therapy and MU1140-S. The Company is focusing its efforts on growing its oral probiotic business both with its branded Evora products and through licensing and private label sales (with ProBiora3). Its SMaRT Replacement Therapy is designed to be a treatment applied to the teeth that has the potential to offer protection against dental caries, or tooth decay.
ProBiora3 Oral Care Probiotics
ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 , andStreptococcus rattus JH145. The Company promotes ProBiora3 as the active ingredient in its consumer branded products, including EvoraPlus, EvoraKids and EvoraPet, and the professional branded product, EvoraPro. EvoraPlus and EvoraKids are flavored probiotic mints intended for daily use by adults and children, respectively, after brushing their teeth. EvoraPet is focused companion pets, such as cats and dogs, and comes in a tasteless and odorless powder form. In addition to its house-branded products, it also markets ProBiora3 as an active ingredient for private label products, as well as in bulk for licensing applications.
The Company markets products containing ProBiora3 under its own house brand names, and have branded ProBiora3 as an active ingredient for licensing and private labeling. Its house brand products contain different ratios, or blends, of the three natural strains contained in ProBiora3, which vary depending on the intended use of the product. EvoraPlus is a product with equal weight of all three strains that is designed for the general consumer market. EvoraPlus is a mint-flavored probiotic tablet packaged in a 30-unit bottle, representing a one-month supply. EvoraKids is a product that has higher levels of S. rattus, which addresses dental health, but reduced levels of S. oralis and S. uberis. EvoraKids is a fruit-flavored chewable probiotic tablet packaged in a 30-unit bottle, representing a one-month supply. EvoraPet is a product that has higher levels of S. oralis and S. uberis, which addresses tooth staining and breath problems common to dogs and cats, but has reduced levels of S. rattus. EvoraPet comes in powder form, which is odorless and tasteless. EvoraPro is a professional strength version of EvoraPlus that is designed for the dental office channel. EvoraPro is a mint-flavored probiotic tablet packaged in a 30-unit bottle, representing a one-month supply.
LPT3-04 Weight Loss Product
LPT3-04 is a naturally occurring compound, which is consumed in the human diet in small amounts. It has conducted a human clinical trial on LPT3-04.
SMaRT Replacement Therapy
SMaRT Replacement Therapy is designed to be a topical treatment applied to the teeth. During the fiscal year ended December 31, 2011, it initiated a second Phase-I clinical trial in the United States with an attenuated version of its SMaRT Replacement Therapy, at the phase-I facilities of its Clinical Research Group (CRO) partner, PRA International.
The Company’s replacement therapy technology is based on the creation of a genetically altered strain of S. mutans, called SMaRT. Its SMaRT strain is engineered to have a selective colonization advantage over native S. mutans strains in that SMaRT produces minute amounts of a lantibiotic, which kills off the native strains but leaves the SMaRT strain unharmed.
MU1140 and Other Lantibiotics
MU1140 is a antibiotic, which is produced by the parent of the SMaRT strain, and it has produced a synthetic version of MU1140 known as MU1140-S. MU1140 is active against all Gram positive bacteria against which it has been tested. The key technology, which enables its production of MU1140-S is its Differentially Protected Orthogonal Lanthionine Technology (DPOLT), which is a organic chemistry synthesis platform developed by its scientific team. MU1140 has demonstrated against a range of disease-causing Gram positive bacteria, including MRSA, VRE, C. diff., Mycobacterium tuberculosis, orM. tuberculosis, and anthrax.
The Company competes with BioGaia AB/Sunstar, BLIS Technologies, Ltd., Colgate, Procter & Gamble, Unilever, GlaxoSmithKline and Dentsply.
Suite 125, 4902 Eisenhower Blvd
TAMPA FL 33634